Sign In
Buy FHTX
$3.64
+0.0100 (+0.275%)
At Close: Jun 03, 2026
Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference
07:00am, Friday, 05'th Apr 2024
Company presentation and fireside chat on April 11th at 11:45 a.m. ET Company presentation and fireside chat on April 11th at 11:45 a.m. ET
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
10:56am, Tuesday, 02'nd Apr 2024
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
01:00pm, Wednesday, 13'th Mar 2024
Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
10:56am, Wednesday, 13'th Mar 2024
The consensus price target hints at a 124.3% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
09:21am, Thursday, 07'th Mar 2024
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.69 per share a year ago.
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
07:00am, Thursday, 07'th Mar 2024
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024
Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference
07:00am, Wednesday, 28'th Feb 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
03:46am, Monday, 12'th Feb 2024
Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
11:05am, Friday, 09'th Feb 2024
Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why
01:31pm, Tuesday, 26'th Dec 2023
Foghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%
11:17am, Monday, 11'th Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is quest
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
07:00am, Thursday, 02'nd Nov 2023
CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
